*The abstracts
of the oral presentations are also available by clicking the speakerr's
name below.
Prof.
Glück talked about the latest development of neoadjuvant
chemotherapy and suggested to optimize the current treatment options
and to develop successful therapy according to biology and not only
histo-pathologic features of breast cancer.
Dr.
Chow presented the novel treatment armamentarium for hormone-sensitve
breast cancer patients. He suggested the use of combination of hormonal
therapy with signal transduction inhibitors in order to overcome
the problem of resistance to traditional therapy.
Dr.Pegram
talked about the recent primary systemic therapy for metastatic
breast cancer. Multiple investigational agents are currently under
study to improve the treatment efficacy. Future directions will
include development of targeted biologic agents and small molecules
targeting signaling pathways. He also presented the latest treatment
strategies of using signal transduction inhibitors in solid tumors.
Prof.
Arber summarized latest chemoprevention studies - Adenoma Prevention
with Celecoxib (APC) study, Prevention of Colorectal Sporadic Adenomatous
Polyps (PreSAP) study, and Adenomatous Polyp Prevention on Vioxx
(APPROVe) stduy. He also presented a novel selective gene targeting
approach to selectively kill cancer cells.
Prof.
Gleave introduced the current approach of intermittent androgen
suppression (IAS) to delay progresson to androgen independence and
the novel targeted gene therapies to enhance tumor cell death after
androgen withdrawal or taxane chemotherapy.
Prof.
Sasano presented the effects aromatase inhibitor on bone in
genetic approach. He commented that the gene induced by the steroidal
AI exemestane demonstrated the possible bone protective effect using
microarray analysis. He also talked about the importance of using
surgical pathology materials to standardize surrogate markers for
molecular therapy.
Dr.
Aapro addressed the problems of long-term treatment with third-generation
anti-aromatase agents in women with breast cancer. The use of bisphosphonates
however reduces the bone loss due to the therapy. He presented the
ongoing clinical trials of using different preventive bisphosphonates.
Prof.
Kumar introduced the nuclear localization of p21-activated kinase
1 (PAK1) which is associated with development of tamoxifen resistance.
He suggsted that tamoxifen resistance might be prevented or reversed
by PAK1 inhibition.
Dr.
Vijver presented the gene expression profiling to predict the
outcome and response to breast cancer therapy. A previously defined
gene expression profile of 70 genes is predictive for prognosis
of patients. He concluded that gene expression profiling will lead
to novel diagnostic test in clinical practice.
Prof.
Cao focused on lymphangiogenesis and lymphatic metastasis in
cancers. He identified several lymphangiogenic factors such as VEGF-A,
VEGF-C or PDGF-BB which promotes lymphangiogenesis and metastasis.
Prof.
Wong talked about the use of cyclooxygenase-2 (COX-2) inhibitors
to prevent gastric cancer. In gastric cancer, COX-2 is over-expressed
and serves as potential target for prevention and treatment. Both
in vivo and in vitro studies testifies the promosing
role of COX-2 inhibitors in the prevention of gastric cancer.
Prof.
Leung addressed molecular subtypes of colorectal cancer (CRC).
Microsatellite instability (MSI) resulting from inactivation of
any components in the DNA mismatch repair complex causes development
of CRC. More understanding of the cause of MSI helps in prevention,
diagnosis, and treatment of CRC.
Friday,
September 22
| Title |
Topic |
Chairperson |
Speakers |
| Poster
Discussion Session and Opening Ceremony |
| Session
1 |
Neoadjuvant
Therapy
Neoadjuvant Chemotherapy: New Developments
& Changing Paradigms
Neoadjuvant Hormonal Therapy of Breast
Cancer
Primary Systemic Therapy for Metastatic
Breast Cancer |
Masakazu
Toi |
Prof. S. Glück
Dr.
L.W.C. Chow
Dr.
M. Pegram |
| Session
2 |
Novel
Cancer Therapy I
Prevention of Colorectal CancerL is
Chemoprevention Still a Valid Option?
Targeting Stress-induced Cytoprotective
Chaperones, Chaperones, Clusterin and Hsp27, to Enhance Chemosensitivity
in mHRPC
A Novel Selective Gene Targeting Approach
to Selectively Kill Cancer Cells, In Vitro and
In Vivo, with Hyperactive �]-catenin
or Ras Pathways |
Simon
Leung |
Prof.
N. Arber
Prof.
M. Gleave
Prof.
N. Arber |
Saturday,
September 23
| Title |
Topic |
Chairperson |
Speakers |
| Session
3 |
Novel
Cancer Therapy II
Signal Transduction for Cancers
Targeting the IGF-1 Axis in Hormone
Sensitive Breast and Prostate Cancer |
Stefan
Glück |
Dr.
M. Pegram
Prof.
M. Gleave
|
| Session
4 |
Endocrine
Therapy Associated Changes
Aromatase Inhibitors and Bone
Improving Bone Health: Bisphosphonates
during Anti-Aromatase Therapy
Nuclear PAK1 and Tamoxifen Resistance |
Louis
Chow |
Prof. H. Sasano
Dr.
M. Aapro
Prof.
R. Kumar |
| Session
5 |
Prediction
of Response to Breast Cancer
Prediction of Outcome and Response
to Therapy in Breast Cancer by Gene Expression Profiling
An Analysis of Surrogate Marker for Molecular
Therapy in Breast Cancer Using Surgical Pathology Materials
|
Masakazu
Toi |
Dr.
van de Vijver
Prof. H. Sasano |
| Session
6 |
Prediction
of Response to Solid Tumors
Lymphangiogenesis and Lymphatic Metastasis
Use of Cyclooxygenase Inhibitors in Prevention
of Gastric Cancers
Molecular Subtypes of Colorectal Cancer
- Implications for Genetic Susceptability, Prognosis and Response
to Treatment |
Shinji
Ohno |
Prof.
Y. Cao
Prof.
B. Wong
Prof.
S.Y. Leung |
| Closing
Ceremony and Gala Dinner |
4th
Annual Conference will be held in Japan in 2007
